Long-term estimate of quality-adjusted life expectancy for nilotinib and imatinib as first-line treatment for newly diagnosed patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in the chronic phase (CML-CP).

Abstract

6570 Background: In the ENESTnd study, the 12-month rates of major molecular (MMR) and complete cytogenetic (CCyR) responses were significantly higher in newly diagnosed Ph+ CML-CP patients initiat...